Skip to content
Combined Shape
Created with Sketch.
Page 1
Created with Sketch.
Page 1
Created with Sketch.
COVID-19
EyewireTV
Stocks
Interests
Cataract and Refractive
Eye-Grey
Created with Sketch.
Glaucoma
Gauge-Grey
Created with Sketch.
Healthcare
Cross-Grey
Created with Sketch.
Optometry
Laser-Grey
Created with Sketch.
Product Approvals
Gear-Grey
Created with Sketch.
Retina
Laser-Grey
Created with Sketch.
More
Events
Subscribe
About
Send a Tip
Advertising
Privacy Policy
COVID-19
EyewireTV
Stocks
Interests
Cataract and Refractive
Eye-Grey
Created with Sketch.
Glaucoma
Gauge-Grey
Created with Sketch.
Healthcare
Cross-Grey
Created with Sketch.
Optometry
Laser-Grey
Created with Sketch.
Product Approvals
Gear-Grey
Created with Sketch.
Retina
Laser-Grey
Created with Sketch.
Events
About
Send a Tip
Advertising
Privacy Policy
Page 1
Created with Sketch.
iDose TR
01.13.21
Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study
Source: Glaukos
View more stories
Home
Menu
Share
